Repare Therapeutics (NASDAQ:RPTX) Given New $3.00 Price Target at HC Wainwright

Repare Therapeutics (NASDAQ:RPTX) had its price target reduced by HC Wainwright from $5.00 to $3.00 in a research report sent to investors on Monday, Marketbeat reports. HC Wainwright currently has a buy rating on the stock.

RPTX has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Repare Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.50.

Repare Therapeutics Trading Down 4.6%

Shares of RPTX opened at $1.87 on Monday. The business’s 50 day moving average is $1.75 and its 200 day moving average is $1.53. The company has a market capitalization of $80.34 million, a PE ratio of -0.72 and a beta of 1.08. Repare Therapeutics has a 12-month low of $0.89 and a 12-month high of $4.07.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.17. The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $2.50 million. Equities research analysts predict that Repare Therapeutics will post -2.04 earnings per share for the current year.

Hedge Funds Weigh In On Repare Therapeutics

Several large investors have recently modified their holdings of RPTX. Rangeley Capital LLC bought a new position in shares of Repare Therapeutics during the 2nd quarter valued at approximately $494,000. Acadian Asset Management LLC boosted its holdings in Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock valued at $624,000 after acquiring an additional 168,230 shares during the period. Militia Capital Partners LP purchased a new position in Repare Therapeutics during the 2nd quarter valued at $166,000. Affinity Asset Advisors LLC boosted its holdings in Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock valued at $197,000 after acquiring an additional 100,000 shares during the period. Finally, XTX Topco Ltd purchased a new position in Repare Therapeutics during the 2nd quarter valued at $60,000. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.